|
Jun 27
|
Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right
|
|
Jun 24
|
XOMA Royalty (XOMA) Moves 9.0% Higher: Will This Strength Last?
|
|
Jun 18
|
XOMA Royalty Declares Quarterly Preferred Stock Dividends
|
|
May 27
|
XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million
|
|
Feb 24
|
XOMA Royalty to Present at Investor Conferences in March
|
|
Feb 4
|
XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
|
|
Sep 10
|
High Growth Tech Stocks In The United States To Watch
|
|
Jun 21
|
Xoma (XOMA) Soars 15.6%: Is Further Upside Left in the Stock?
|
|
Feb 28
|
XOMA to Present at Upcoming Investor Conferences in March
|
|
Jan 11
|
FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx
|
|
Dec 20
|
XOMA Declares Quarterly Preferred Stock Dividends
|
|
Dec 19
|
XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® Royalties
|